Compare SOBR & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOBR | CANF |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.5M |
| IPO Year | N/A | N/A |
| Metric | SOBR | CANF |
|---|---|---|
| Price | $2.12 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | ★ 7.4M | 564.4K |
| Earning Date | 11-12-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $364,164.00 | ★ $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 98.07 | N/A |
| 52 Week Low | $1.27 | $3.36 |
| 52 Week High | $14.20 | $46.60 |
| Indicator | SOBR | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 56.55 | 73.84 |
| Support Level | $2.05 | $3.87 |
| Resistance Level | $2.22 | $4.43 |
| Average True Range (ATR) | 0.21 | 0.34 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 68.35 | 83.09 |
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.